ZA201500103B - Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy - Google Patents

Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy

Info

Publication number
ZA201500103B
ZA201500103B ZA2015/00103A ZA201500103A ZA201500103B ZA 201500103 B ZA201500103 B ZA 201500103B ZA 2015/00103 A ZA2015/00103 A ZA 2015/00103A ZA 201500103 A ZA201500103 A ZA 201500103A ZA 201500103 B ZA201500103 B ZA 201500103B
Authority
ZA
South Africa
Prior art keywords
converting enzyme
enzyme inhibitors
optic
angiotensin converting
congenital
Prior art date
Application number
ZA2015/00103A
Other languages
English (en)
Inventor
Raouf Rekik
Original Assignee
Raouf Rekik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raouf Rekik filed Critical Raouf Rekik
Publication of ZA201500103B publication Critical patent/ZA201500103B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2015/00103A 2012-06-29 2015-01-07 Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy ZA201500103B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TN20120343 2012-06-29
PCT/IB2013/001375 WO2014001889A1 (en) 2012-06-29 2013-06-28 Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy

Publications (1)

Publication Number Publication Date
ZA201500103B true ZA201500103B (en) 2016-05-25

Family

ID=52471712

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/00103A ZA201500103B (en) 2012-06-29 2015-01-07 Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy

Country Status (7)

Country Link
US (1) US9730949B2 (enExample)
EP (1) EP2866805A1 (enExample)
JP (1) JP6238977B2 (enExample)
CA (1) CA2877590A1 (enExample)
RU (1) RU2658461C2 (enExample)
WO (1) WO2014001889A1 (enExample)
ZA (1) ZA201500103B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108452309B (zh) * 2018-03-05 2019-08-23 佳木斯大学附属第一医院 一种用于预防或治疗视神经炎的药物组合物及其制备方法
RU2704013C1 (ru) * 2019-04-18 2019-10-23 ФГБНУ "НИИ глазных болезней" Способ коррекции окислительного стресса при наследственной оптической нейропатии Лебера

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
MXPA01012907A (es) * 1999-06-16 2003-06-24 Rekik Elyes Ben Mohamed Raouf Medicamentos oftalmologicos neutro - protectores y retino - protectores.
FR2826276A1 (fr) * 2001-06-20 2002-12-27 Raouf Rekik Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
RU2281023C2 (ru) * 2004-10-26 2006-08-10 Наталия Ивановна Курышева Способ прогнозирования течения глаукоматозной оптической нейропатии
EP3332766A1 (en) 2009-04-28 2018-06-13 BioElectron Technology Corporation Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur

Also Published As

Publication number Publication date
JP2015522000A (ja) 2015-08-03
RU2658461C2 (ru) 2018-06-21
US20150174146A1 (en) 2015-06-25
WO2014001889A1 (en) 2014-01-03
US9730949B2 (en) 2017-08-15
CA2877590A1 (en) 2014-01-03
EP2866805A1 (en) 2015-05-06
JP6238977B2 (ja) 2017-11-29
RU2014152906A (ru) 2016-08-20

Similar Documents

Publication Publication Date Title
IL252108A0 (en) cdk inhibitors
IL228003A0 (en) System and method for app approval
GB201004179D0 (en) Enzyme inhibitors
EP2609733A4 (en) OPERATING TECHNIQUES BASED ON AN OBJECT
GB201004178D0 (en) Enzyme inhibitors
EP2740064A4 (en) Sandboxing technology for webruntime system
PL2539080T3 (pl) Sposób powlekania komponentów
WO2012088388A9 (en) Treating multiple myeloma
HUE048470T2 (hu) Támaszték implantátumhoz
GB2507704B (en) Tightening system
IL222607A0 (en) Method for disinfecting surfaces
EP2486890A4 (en) SUPPORT FOR AN IMPLANT
EP2538264A4 (en) OPTICAL SYSTEM FOR FORMING A QUADRATIC OPTICAL PATH AND METHOD THEREFOR
PL2912021T3 (pl) Inhibitory agrekanazy
GB201108979D0 (en) Time alignment for an amplification stage
PL2748267T3 (pl) Sposób ochrony powierzchni
EG26972A (en) Method for treating waste
PL2380747T3 (pl) Sposób zapewniania paneli
ZA201500103B (en) Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy
GB201007755D0 (en) Method and system for machine-learning based profiling
GB201223308D0 (en) Enzyme inhibitors
GB201009629D0 (en) Antibacterial enzyme inhibitors
GB201210390D0 (en) Antibacterial enzyme inhibitors
GB201200094D0 (en) Antibacterial enzyme inhibitors
AU2012901720A0 (en) Anti-tagging for local variables